COMBINATION THERAPY TECHNIQUE FOR Axl INHIBITORY AGENT AND EGFR TYROSINE KINASE INHIBITOR
申请人:Daiichi Sankyo Company, Limited
公开号:EP3603638A1
公开(公告)日:2020-02-05
The present invention provides a medicament comprising a compound represented by general formula (1) which has Axl inhibitory activity, and an EGFR tyrosine kinase inhibitor in combination, and a method for treating cancer using this combination. The present invention provides an excellent medicament and method for treating cancer which is highly effective for inhibiting resistance to an EGFR tyrosine kinase inhibitor in cancer treatment, and causes less adverse reactions such as weight loss.
本发明提供了一种由具有 Axl 抑制活性的通式(1)所代表的化合物和表皮生长因子受体酪氨酸激酶抑制剂组合而成的药物,以及使用该组合治疗癌症的方法。本发明提供了一种治疗癌症的优良药物和方法,它在癌症治疗中对抑制表皮生长因子受体酪氨酸激酶抑制剂的耐药性非常有效,而且引起的不良反应(如体重减轻)较少。